GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Telomir Pharmaceuticals
Telomir, a biotech company working in the field of anti-aging, is a highly speculative bet on its scientific platform. Its price is driven not by financial performance, but by the hype surrounding longevity and news from early research.
Share prices of companies in the market segment - Pharma other
Telomir Pharmaceuticals is a biopharmaceutical company developing drugs to combat aging and age-related diseases by targeting telomeres. We've classified it in the "Other Pharma" category. The chart below shows how investors view this ambitious anti-aging sector.
Broad Market Index - GURU.Markets
Telomir Pharmaceuticals is a biopharmaceutical company developing drugs to combat aging and age-related diseases by targeting telomeres. As a component of the GURU.Markets index, it represents the ambitious anti-aging healthcare sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
TELO - Daily change in the company's share price Telomir Pharmaceuticals
For Telomir Pharmaceuticals, Inc., a company focused on anti-aging medicine, daily volatility reflects sensitivity to scientific data. This metric is an important element in formulas assessing the risks and potential of this innovative field.
Daily change in the price of a set of shares in a market segment - Pharma other
Telomir Pharmaceuticals, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with TELO, which focuses on anti-aging medicine, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Telomir Pharmaceuticals is a biotech company focused on anti-aging. Its shares are a bet on a scientific revolution in medicine. Their high volatility, driven by research results, is part of the dynamic of the innovation sector, which impacts the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Telomir Pharmaceuticals
Telomir Pharmaceuticals' year-to-date performance is a story of drug development targeting age-related diseases. Its 12-month market cap is entirely dependent on progress in its preclinical and clinical programs based on telomerase inhibition. Its valuation is a bet on a breakthrough in anti-aging medicine.
Annual dynamics of market capitalization of the market segment - Pharma other
Telomir, as an early-stage biotech company, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its anti-aging research. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Telomir is a highly speculative biotech company working in the anti-aging field. Its stock price since its IPO has had nothing to do with fundamentals or economics, but has been driven by rumors, hype, and investor confidence in the potential of its developments.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Telomir Pharmaceuticals
Telomir Pharmaceuticals is a preclinical biotech company working in the field of anti-aging. Its monthly valuation is based solely on expectations and the potential of its scientific platform. Any news about its developments could trigger a strong reaction.
Monthly dynamics of market capitalization of the market segment - Pharma other
Telomir Pharmaceuticals is a biotech company at the forefront of aging science. It develops drugs that have the potential to reverse age-related changes at the cellular level. The chart below reflects the sentiment in the pharmaceutical sector, where anti-aging is the holy grail.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Telomir Pharmaceuticals is a preclinical biotech company working on aging. Its shares are a pure venture bet on a scientific hypothesis. Their performance is completely unrelated to the market and will be determined solely by lab news and future research results.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Telomir Pharmaceuticals
Telomir Pharmaceuticals is a biotech company operating in the promising but speculative field of anti-aging. Its weekly stock price reflects its high risk and potential return. Any press releases about scientific developments or research trigger extreme market reactions.
Weekly dynamics of market capitalization of the market segment - Pharma other
Telomir Pharmaceuticals is a biotech company operating in the promising but speculative field of anti-aging. Its weekly stock price reflects its high risk and potential return. Any press releases about scientific developments or research trigger extreme market reactions.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Telomir, a biotech company, lives in a world of its own. Its performance is driven by news of scientific breakthroughs. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall on company-specific events, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
TELO - Market capitalization of the company Telomir Pharmaceuticals
Telomir Pharmaceuticals' market cap is a futuristic story built on the hypothesis of fighting aging by targeting telomeres. The stock price of this early-stage biotech company reflects pure speculation and investor faith in its potential to revolutionize longevity medicine. Its dynamics are a visualization of enormous hopes and risks.
TELO - Share of the company's market capitalization Telomir Pharmaceuticals within the market segment - Pharma other
Telomir Pharmaceuticals is a preclinical pharmaceutical company researching drugs with potential applications in anti-aging and cancer treatment. Its share of its segment's market capitalization reflects investors' speculative interest in its breakthrough idea. The chart below demonstrates the extremely high valuation volatility.
Market capitalization of the market segment - Pharma other
Telomir Pharmaceuticals is developing drugs aimed at combating aging and age-related diseases. The chart below shows the overall market capitalization of the pharmaceutical sector. It reflects the enormous, yet high-risk, interest in "longevity science," where the potential market is enormous, but scientific evidence is only just beginning to emerge.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents a scientific quest for the secret to youth. Telomir Pharmaceuticals is developing drugs aimed at lengthening telomeres, which could slow aging. Its line on the graph is a pure, high-risk bet on one of the most fundamental and daring approaches in modern biomedicine.
Book value capitalization of the company, segment and market as a whole
TELO - Book value capitalization of the company Telomir Pharmaceuticals
Telomir Pharmaceuticals' foundation is its intellectual property, TELOMIR-1, a drug designed to inhibit telomerase and potentially treat age-related diseases and cancer. This represents cutting-edge scientific capital. The chart below shows how the company is accumulating resources to test its ambitious scientific hypothesis through research.
TELO - Share of the company's book capitalization Telomir Pharmaceuticals within the market segment - Pharma other
Telomir Pharmaceuticals is a biotech company working on anti-aging drugs. Its early-stage assets are patents and scientific data. The chart shows a minimal share of physical assets, as its value lies in the potential of its scientific discoveries.
Market segment balance sheet capitalization - Pharma other
Biopharmaceuticals, as the BCap_Seg chart shows, require investment in science, not factories. Telomir Pharmaceuticals, at the forefront of aging research, is an example of a science-intensive rather than capital-intensive business. Its assets are potential discoveries, not production lines.
Book value of all companies included in the broad market index - GURU.Markets
Telomir Pharmaceuticals' assets include intellectual property and capital for developing anti-aging drugs. Its book value provides the financial foundation for research that could lead to the creation of tangible, physical products that impact the aging process.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Telomir Pharmaceuticals
Telomir Pharmaceuticals is working on drugs with potential life extension potential (telomerase inhibition). This is one of the most speculative areas in biotech. The MvsBCap chart here is a pure bet on a scientific breakthrough. Its valuation will be divorced from any other assets and will reflect the hype and expectations surrounding the eternal topic of anti-aging.
Market to book capitalization ratio in a market segment - Pharma other
Telomir Pharmaceuticals is developing anti-aging drugs. As a company at the forefront of science, its valuation is based on the potential of its breakthrough technology. The chart reflects investors' high expectations for the future of its developments.
Market to book capitalization ratio for the market as a whole
Telomir Pharmaceuticals is developing drugs aimed at slowing the aging process. This is one of the most ambitious goals in medicine. Its market valuation reflects investors' bets on a scientific breakthrough in this field. The book value is almost irrelevant compared to the potential future market size.
Debts of the company, segment and market as a whole
TELO - Company debts Telomir Pharmaceuticals
Telomir Pharmaceuticals is a preclinical biotech company researching drugs with potential anti-aging properties. Its entire capital is dedicated to fundamental research and development. This chart reflects the financial position of a science-intensive startup taking its first steps in one of the most ambitious areas of modern medicine.
Market segment debts - Pharma other
Telomir Pharmaceuticals is a preclinical biotech company exploring approaches to treating aging-related diseases. Funding at the earliest stages of research is extremely risky. This chart shows how the company structures its capital for fundamental research, long before human trials begin.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Telomir Pharmaceuticals
Telomir Pharmaceuticals is developing anti-aging drugs. This chart reflects the company's reliance on debt to finance its ambitious and long-term research. High debt in such an innovative yet risky field means the company's future depends entirely on the success of its developments.
Market segment debt to market segment book capitalization - Pharma other
Telomir Pharmaceuticals is working on drugs targeting the aging process, one of the most ambitious areas in pharmaceuticals. The chart shows the sector's debt load, giving an idea of how typical the company's financial strategy for funding such long-term and risky research is for pioneers in this field.
Debt to book value of all companies in the market
Telomir Pharmaceuticals is developing drugs aimed at combating aging processes at the cellular level. The total debt-to-equity ratio shown in this chart provides a backdrop for the biotech industry. The availability of long-term, "risky" investments required for such breakthrough research is highly dependent on overall market stability.
P/E of the company, segment and market as a whole
P/E - Telomir Pharmaceuticals
This chart of Telomir Pharmaceuticals, a company researching aging processes, reflects speculative hopes for "eternal youth." Any reading on it would reflect investors' faith in a scientific breakthrough capable of creating a multi-billion dollar market, rather than an assessment of the company's current financial performance.
P/E of the market segment - Pharma other
This chart shows the average P/E for the pharmaceutical industry, where Telomir researches aging processes. This metric serves as a backdrop against which any valuation of Telomir would be purely speculative, based on faith in a scientific breakthrough rather than on comparisons with traditional pharmaceutical companies with established sales.
P/E of the market as a whole
Telomir Pharmaceuticals is a biotech company working on drugs that could potentially slow the aging process and treat age-related diseases. This is an ambitious and high-risk field. This chart shows investors' risk appetite. It helps us understand whether Telomir's valuation is a speculative bet on a breakthrough in longevity or is supported by solid scientific data.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Telomir Pharmaceuticals
Telomir Pharmaceuticals is developing drugs to combat aging and age-related diseases by targeting telomeres. This is an ambitious and risky field. The company's valuation is a bet on a scientific breakthrough. This chart shows analysts' confidence in the company's ability to prove its hypothesis and create a working drug.
%20P%2FE%20Telomir%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Telomir-Pharmaceuticals&v=1772513802228 "Chart of the company's future (projected) P/E Telomir Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma other
Telomir Pharmaceuticals is exploring the potential of new drugs aimed at combating aging and age-related diseases by targeting telomeres. This graph shows its future profitability expectations, allowing us to assess how highly the market values its ambitious scientific approach to one of biology's fundamental problems.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772513802233 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Telomir Pharmaceuticals is exploring the potential of telomerase inhibitors to combat aging and age-related diseases. This is an extremely ambitious goal, requiring long-term investment. This chart, showing how much the market is willing to pay for future revenue, reflects the investment climate. Market optimism is critical for attracting capital into such breakthrough areas.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513802254 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Telomir Pharmaceuticals
Telomir Pharmaceuticals is developing drugs aimed at slowing the aging process by targeting telomeres. The company's profitability is a long-term goal, and its current finances are spent on breakthrough research. This chart shows the investment phase, where every dollar is invested in science that has the potential to change the paradigm of medicine.
Profit of companies in the market segment - Pharma other
Telomir Pharmaceuticals is exploring the potential of drugs to combat aging and age-related diseases by targeting telomeres. This is one of the most ambitious areas in biotechnology. This graph illustrates the overall dynamics of the pharmaceutical industry, where research aimed at extending healthy lifespan could open multibillion-dollar markets in the future.
Overall market profit
Telomir Pharmaceuticals is working on drugs that potentially slow down aging. This is an area with enormous potential, but one that requires colossal investment. The overall economic climate, reflected in this chart, determines how much investors are willing to invest in such long-term and ambitious scientific goals.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Telomir Pharmaceuticals
Telomir Pharmaceuticals is developing drugs aimed at slowing the aging process and treating age-related diseases. This is an ambitious goal at the cutting edge of science. This chart shows how analysts assess the likelihood of a scientific breakthrough and the company's potential commercial success in this revolutionary field of medicine.
%20profit%20of%20the%20company%20Telomir%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Telomir-Pharmaceuticals&v=1772513802303 "Graph of future (projected) profit of the company Telomir Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma other
Telomir Pharmaceuticals is a biotech company working in the promising field of anti-aging. Its research focuses on telomerase inhibition for potential rejuvenation and treatment of age-related diseases. This chart shows profitability forecasts for the biotech sector, reflecting investor interest in breakthrough longevity technologies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772513802305 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Telomir Pharmaceuticals is conducting anti-aging research. This is a promising area, but one that requires significant investment. The total market return forecast shown here shapes the investment climate. During periods of expected growth, investors are more inclined to fund ambitious and long-term projects like those being pursued by Telomir.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513802325 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Telomir Pharmaceuticals
Telomir Pharmaceuticals is working on drugs with potential to extend life. This chart reflects the enormous expectations. For a company in such a breakthrough field, market capitalization relative to revenue reflects the degree of investor confidence in its revolutionary scientific idea.
P/S market segment - Pharma other
Telomir Pharmaceuticals is developing drugs aimed at combating aging and age-related diseases by targeting telomeres. This chart shows the average revenue estimate in the biotech sector. It allows us to estimate the premium investors are placing on Telomir's potentially revolutionary approach to extending healthy human life.
P/S of the market as a whole
Telomir Pharmaceuticals is developing drugs aimed at slowing the aging process and treating age-related diseases by targeting telomeres. This is one of the most ambitious goals in medicine. This chart, showing the average market revenue estimates, vividly demonstrates the enormous expectations that can be placed on biotech companies with potentially revolutionary ideas.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Telomir Pharmaceuticals
Telomir Pharmaceuticals is developing drugs aimed at slowing the aging process by targeting telomeres. This chart reflects investors' speculative expectations for a breakthrough in anti-aging medicine. The valuation is based entirely on future prospects if its revolutionary approach proves successful in clinical trials.
%20P%2FS%20Telomir%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Telomir-Pharmaceuticals&v=1772513802361 "The graph of the company's future (projected) P/S Telomir Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma other
Telomir Pharmaceuticals is a biopharmaceutical company exploring new approaches to treating age-related diseases and cancer by targeting telomeres. This is a cutting-edge, but high-risk, scientific approach. This chart shows how the market assesses its long-term potential, should its hypotheses be confirmed, compared to the pharmaceutical industry.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772513802376 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Telomir Pharmaceuticals is working on anti-aging drugs, one of the most ambitious areas in biotech. This graph, reflecting investors' willingness to invest in breakthrough but high-risk ideas, is a key factor for Telomir. Market optimism is a prerequisite for funding such long-term and capital-intensive projects.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513802382 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Telomir Pharmaceuticals
Telomir Pharmaceuticals is a biotech company developing drugs that have the potential to combat aging and age-related diseases. This chart reflects early-stage funding, likely from investors. It doesn't represent commercial revenue, but rather funding for ambitious scientific research into healthy life extension.
Sales of companies in the market segment - Pharma other
Telomir Pharmaceuticals is a pharmaceutical company developing telomere-lengthening drugs to combat age-related diseases and improve health. Its operations are segmented into various research programs. This chart shows the financial flows associated with one of its innovation pipelines.
Overall market sales
Telomir Pharmaceuticals is a company developing drugs that potentially slow the aging process. This is one of the most ambitious areas in biotechnology. The company's success depends not on economics, but on fundamental scientific discoveries. If a breakthrough occurs, it could create a huge new market for extending healthy lifespan.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Telomir Pharmaceuticals
Telomir Pharmaceuticals is a biopharmaceutical company developing drugs to extend healthy longevity by targeting telomeres. Its future sales forecast is a long-term bet on a breakthrough in anti-aging medicine, reflecting the expected success of its preclinical and future clinical trials.
%20sales%20of%20the%20company%20Telomir%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Telomir-Pharmaceuticals&v=1772513802407 "Schedule of future (projected) sales of the company Telomir Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma other
Telomir Pharmaceuticals is exploring the potential of new drugs aimed at combating aging and age-related diseases. This chart shows expectations for the entire pharmaceutical sector. It reflects analysts' growth forecasts for the anti-aging technology market, allowing us to estimate how large experts believe this new segment could become.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772513802408 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Telomir Pharmaceuticals is researching drugs to slow down aging. This field requires significant long-term investment. This graph of overall sales forecasts reflects the economic confidence investors need to fund such ambitious and risky research projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513802410 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Telomir Pharmaceuticals
Telomir Pharmaceuticals is a biotech company developing therapies to combat aging and related diseases. At the forefront of science, the company actively invests in research. This chart shows its financial position, with current R&D expenditures laying the foundation for potential future breakthroughs.
Market segment marginality - Pharma other
Telomir Pharmaceuticals is a pharmaceutical company working on drugs that may impact the aging process. In this cutting-edge and risky field, operational efficiency lies in conducting research as cost-effectively as possible. The chart shows how the company manages its resources in the race for breakthrough technologies.
Market marginality as a whole
Telomir Pharmaceuticals is a biotech company developing drugs that can impact aging at the cellular level. This is one of the most ambitious areas in medicine. This chart shows the profitability of existing businesses, while TELO's value is determined by the potential of its breakthrough research in longevity.
Employees in the company, segment and market as a whole
Number of employees in the company Telomir Pharmaceuticals
Telomir Pharmaceuticals is exploring a way to combat aging by targeting telomeres. This graph shows the team of scientists at the forefront of this complex field. The size of this team reflects the scale of investment in fundamental research that could one day transform the approach to age-related medicine.
Share of the company's employees Telomir Pharmaceuticals within the market segment - Pharma other
Telomir Pharmaceuticals is working to develop drugs that target the aging process, one of the most ambitious goals in medicine. Research in this area requires a multidisciplinary team of scientists. This chart shows the company's human capital investment in this cutting-edge and potentially revolutionary field of science.
Number of employees in the market segment - Pharma other
Telomir Pharmaceuticals is a preclinical pharmaceutical company researching the relationship between telomeres and aging. This chart reflects employment in the pharmaceutical industry as a whole. The growing number of scientists in the field of anti-aging medicine indicates growing scientific and commercial interest in extending healthy life, a long-term trend for Telomir.
Number of employees in the market as a whole
Telomir Pharmaceuticals develops drugs that target the aging process. This is one of the most promising areas of biotech. This graph shows the current situation, but Telomir is working to create a future where healthy life expectancy increases, and this increase depends on scientific breakthroughs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Telomir Pharmaceuticals (TELO)
Telomir Pharmaceuticals, Inc. is working on drugs that potentially slow aging. This is one of the most ambitious areas in biotech. The high market capitalization per employee in this chart reflects not current revenue, but the enormous potential market and investor confidence in the scientific advancements of a small but cutting-edge team of researchers.
%20of%20the%20company%20Telomir%20Pharmaceuticals%20(TELO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Telomir-Pharmaceuticals-TELO&v=1772513802532 "Chart of market capitalization per employee (in thousands of dollars) of the company Telomir Pharmaceuticals (TELO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Telomir Pharmaceuticals is developing drugs aimed at combating aging and age-related diseases. For a company at the forefront of biotechnology, this metric reflects market expectations for their breakthrough research. It demonstrates the perceived potential of their scientific platform per scientist.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772513802547 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Telomir Pharmaceuticals is a biotech company exploring the potential link between telomere length and the aging process, with the goal of developing drugs to slow it down. This is an extremely ambitious and speculative field. The chart reflects the enormous expectations the market has for the breakthrough research of this small team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513802554 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Telomir Pharmaceuticals (TELO)
Telomir Pharmaceuticals is a biotech company working on an intriguing concept: telomere-lengthening drugs to combat aging and age-related diseases. It's in the extremely early, speculative stages. This graph (deeply negative) shows how much capital the company is burning through per scientist trying to prove its revolutionary concept. This represents pure R&D costs.
%20Chart%20Telomir%20Pharmaceuticals%20(TELO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Telomir-Pharmaceuticals-TELO&v=1772513802570 "Company Profit Per Employee (in thousands of dollars) Chart Telomir Pharmaceuticals (TELO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Telomir Pharmaceuticals develops drugs aimed at combating aging and age-related diseases. In such an innovative field, a small team of scientists plays a key role. This metric reflects their ability to translate scientific hypotheses into profitability, serving as a benchmark for their effectiveness compared to other biotech startups.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772513802575 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Telomir Pharmaceuticals is a preclinical company working in the field of anti-aging (age-tech). This is one of the most venture-backed areas of biotech. Negative profit per employee is the norm here. The graph reflects the "cost" of maintaining an R&D team attempting to create a fundamentally new technology without any commercial products in the foreseeable future.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513802584 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Telomir Pharmaceuticals (TELO)
Telomir Pharmaceuticals is a preclinical pharmaceutical company exploring the potential of life-extending drugs. At this stage, there is no revenue per employee. This graph is purely hypothetical, reflecting the future hope that a scientific breakthrough will lead to the creation of a commercial product.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Telomir-Pharmaceuticals-TELO&v=1772513802589 "Sales chart per company employee Telomir Pharmaceuticals (TELO)")
Sales per employee in the market segment - Pharma other
Telomir Pharmaceuticals is an early-stage company researching the relationship between telomeres and aging, with the goal of developing therapies for age-related diseases. This chart compares revenue per employee (R&D) to the industry average, which for a company without a product reflects its current stage and the effectiveness of its R&D budget management.
Sales per employee for the market as a whole
Telomir Pharmaceuticals is a very early-stage biotech company working in the ambitious field of anti-aging. The company has no approved drugs or commercial revenue. All its employees are engaged in R&D. This graph would show $0, typical for a preclinical biotech company living on venture capital while waiting for a breakthrough.
Short shares by company, segment and market as a whole
Shares shorted by company Telomir Pharmaceuticals (TELO)
Telomir Pharmaceuticals is a biotech company with an ambitious goal: combating aging (telomeres). This is one of the most speculative areas in medicine, where science still lags far behind the hype. This chart shows the number of investors who consider this topic pure speculation and don't believe it will yield any tangible results.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Telomir-Pharmaceuticals-TELO&v=1772513802639 "Short Shares Chart for the Company Telomir Pharmaceuticals (TELO)")
Shares shorted by market segment - Pharma other
Telomir Pharmaceuticals is a biotech company working on the intriguing but highly speculative topic of "telomere extension" to combat aging and age-related diseases. This chart shows the odds against the "anti-aging" sector, reflecting the extreme skepticism of investors regarding this scientific field, which is still far from a commercial product.
Shares shorted by the overall market
Telomir (TELO) is a biotech company working on life extension. It's one of the most speculative and long-term bets. When this market fear indicator rises, investors immediately "flee risk." They are the first to sell off unprofitable, R&D-focused companies like TELO.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Telomir Pharmaceuticals (TELO)
Telomir Pharmaceuticals is a biotech company working in anti-aging medicine and cancer treatments by targeting telomeres. This is a highly ambitious and speculative topic. This chart tracks the hype surrounding their research, highlighting overbought peaks (above 70) and moments when investor confidence wanes (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Telomir-Pharmaceuticals-TELO&v=1772513802670 "RSI 14 indicator chart for the company's stock Telomir Pharmaceuticals (TELO)")
RSI 14 Market Segment - Pharma other
Telomir Pharmaceuticals is a preclinical biotech company researching telomere-lengthening drugs for the treatment of age-related diseases and cancer. This chart measures the collective excitement in the biotech sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
For Telomir Pharmaceuticals, a biotech company in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TELO (Telomir Pharmaceuticals)
Telomir Pharmaceuticals is a biotech company working on telomere-related drugs, which offer potential in the field of aging. This chart shows the average price target from analysts. Their forecasts are based not on current earnings, but on an assessment of the scientific potential of the TELO platform and the likelihood of success of its developments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TELO-Telomir-Pharmaceuticals&v=1772513802702 "A chart showing analyst consensus forecasts for the expected stock price. TELO (Telomir Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price TELO (Telomir Pharmaceuticals)
Telomir Pharmaceuticals is a preclinical biotech company whose ambition is to combat aging by lengthening telomeres (the drug TELOMIR-1). This chart shows the potential experts see in this futuristic research. It measures the gap between the current price and the consensus estimate. For a venture-backed company like this, this reflects analysts' faith in their scientific breakthrough.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TELO-Telomir-Pharmaceuticals&v=1772513802722 "A chart showing the difference between the consensus forecast and the actual stock price. TELO (Telomir Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Telomir Pharmaceuticals is a biotech company developing drugs (TELOMIR-1) aimed at lengthening telomeres to combat aging. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe in a breakthrough in "anti-aging drugs" or consider the sector too speculative.
Analysts' consensus forecast for the overall market share price
Telomir Pharmaceuticals is an early-stage biotech company working on the "holy grail": telomere-targeted rejuvenation technology. This chart shows the overall market "risk appetite." For Telomir, whose value is based on pure expectations, overall market optimism (risk appetite) is critical to attracting the massive capital required for years of research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Telomir Pharmaceuticals
Telomir is a biotech company pursuing the Holy Grail: fighting aging through telomere restoration. It's a pure R&D bet on fundamental science. This chart is a comprehensive indicator. It doesn't measure profit (they don't have any), but rather aggregates their scientific progress, the strength of their patents, and the market's speculative belief that their approach could one day transform medicine.
AKIMA Market Segment Index - Pharma other
Telomir Pharmaceuticals (TELO) is pursuing one of the most ambitious goals in healthcare: reversing age-related decline by targeting telomeres. This chart shows the average index value for the pharmaceutical segment. It provides investors with a benchmark for assessing whether this high-risk/high-reward approach is valued differently than its competitors.
The AKIM Index for the overall market
Telomir Pharmaceuticals is a preclinical pharmaceutical company focused on treating age-related diseases by lengthening telomeres. Its key molecule is TELOMIR-1. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this early-stage scientific "longevity" story compares to overall economic trends.
